2seventy Bio Shares Fall Premarket on Abecma Expansion Delay

By Colin Kellaher

Shares of 2seventy bio fell more than 10% Monday after the biotechnology company’s efforts to win expanded U.S. approval for its Abecma gene therapy with Bristol Myers Squibb hit a delay.

Bristol Myers and 2seventy said the U.S. Food and Drug Administration won’t meet its Dec. 16 target action date on the companies’ application…